18.09.2018

BioClin Therapeutics Announces New Leadership to Advance Late-Stage Bladder Cancer Development Program

SAN LEANDRO, Calif., September 18, 2018—BioClin Therapeutics, Inc., a privately-held clinical stage drug development company, today announced the appointment of Scott Myers as Chief Executive Officer, and Julie Eastland as Chief Financial Officer and Chief Business Officer. Mr. Myers will also continue in his role as company Chairman.

“We are excited to announce the appointment of Scott Myers as Chief Executive Officer,” said David Kabakoff, Ph.D., Director of BioClin Therapeutics and Executive Partner at Sofinnova Ventures. “Scott’s track record of leadership and shareholder value creation are an excellent fit for our company.”

“We are also pleased to announce the appointment of Julie Eastland as our Chief Financial Officer and Chief Business Officer. Scott and Julie previously partnered to successfully transform Cascadian Therapeutics, leading to its acquisition by Seattle Genetics for $614M earlier this year.”

“On behalf of the entire board, I would like to thank our founding CEO Stephen Lau, who is stepping down, for his exceptional contribution to the company from inception to its current Phase 2 clinical stage. We are grateful that he will continue to serve as an advisor to the company.”

“I have been privileged to lead BioClin over the past 6 years and to have advanced the development of B-701, which is a potential best-in-class therapy for metastatic bladder cancer. I look forward to supporting Scott and team during the transition,” said Stephen Lau, founder of BioClin Therapeutics.

“I’m delighted to welcome Julie Eastland to our management team as our Chief Financial Officer and Chief Business Officer,” said Scott Myers. “Julie has a strong background in finance, business strategy and licensing, having previously worked at a number of publicly traded and private biotechnology companies. Her fundraising and business development experience will prove invaluable as we execute on our clinical development plans and enter the next phase of growth. Julie, I and the entire management team are focused on advancing vofatamab (B-701) into registration trials, keeping BioClin well-funded, and strengthening the company’s market profile.”

Scott Myers was appointed Chairman of BioClin in June 2018. Mr. Myers most recently served as CEO, President and Director of Seattle based, Cascadian Therapeutics (NASDAQ: CASC), an oncology company that was acquired by Seattle Genetics (NASDAQ: SGEN) in March 2018. Prior to Cascadian, Mr. Myers was CEO of Aerocrine AB, a publicly-traded medical device company based in Stockholm, Sweden and Morrisville, NC, that was acquired by Circassia, PLC in 2015. Prior to Aerocrine, Mr. Myers held senior commercial operations, business development, general management and information management positions for UCB SA, a Belgium based biopharmaceutical company, and Johnson & Johnson.

Julie Eastland most recently served as Chief Financial Officer and Chief Business Officer of Cascadian Therapeutics, from September 2010 to May 2018, through the sale and transition of the company to Seattle Genetics. From 2006 to 2010, Ms. Eastland was the Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately-held biotechnology company. Prior to VLST, Ms. Eastland held various financial and strategic management positions at publicly-traded biotechnology companies including Dendreon and Amgen.

About BioClin Therapeutics, Inc. 

BioClin Therapeutics, Inc. is a privately-held, clinical stage biotechnology company developing a targeted biologic for the potential treatment of metastatic bladder cancer. The company is focused on fibroblast growth factor receptor 3, (FGFR3), a driver of metastatic bladder cancer and potentially other cancers. The company’s lead program, vofatamab, also known as B-701, is the only known targeted biologic specific for FGFR3 in clinical development. BioClin has ongoing clinical studies in metastatic bladder cancer including vofatamab monotherapy, and vofatamab in combination with standard-of-care chemotherapy, as well as with pembrolizumab, an immune checkpoint inhibitor. BioClin’s website is: www.bioclintherapeutics.com.

Contact:

Bioclin Therapeutics
Laurence Watts
Principal
Westwicke Partners, LLC
(858) 356-5930
laurence.watts@westwicke.com


Download

Download pdf English